6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial

Pivot, Xavier; Romieu, Gilles; Debled, Marc; Pierga, Jean‐Yves; Kerbrat, Pierre; Bachelot, Thomas; Lortholary, Alain; Espié, Marc; Fumoleau, P.; Serin, D.; Jacquin, Jean‐Philippe; Jouannaud, Christelle; Rios, María; Abadie‐Lacourtoisie, Sophie; Tubiana-Mathieu, Nicole; Cany, Laurent; Catala, Stéphanie; Khayat, David; Pauporté, Iris; Kramar, Andrew

doi:10.1016/s1470-2045(13)70225-0

Cited by 322 publications

(243 citation statements)

References 11 publications

Supporting

Mentioning

226

Contrasting

Unclassified

Order By: Relevance

“…Although lower rates were reported in the HERA (Herceptin Adjuvant) trial with administration of the monoclonal antibody after completion of chemotherapy,37 these likely reflect differences in timing of randomization of the trials, with the latter only reporting events that occurred following completion of adjuvant chemotherapy. In the HERA and PHARE (Protocol for Herceptin as Adjuvant therapy with Reduced Exposure) trials, longer duration of therapy was associated with higher rates of cardiotoxicity 12, 38, 39. Rates of cardiotoxicity appear to be similar when trastuzumab is added to chemotherapy containing epirubicin as opposed to doxorubicin 40, 41, 42, 43.…”

Section: The Cardiac Risks Of Her2 Targeted Therapiesmentioning

confidence: 99%

Cardiotoxicity From Human Epidermal Growth Factor Receptor‐2 (HER2) Targeted Therapies

Florido

Smith

Cuomo

et al. 2017

JAHA

View full text Add to dashboard Cite

Section: The Cardiac Risks Of Her2 Targeted Therapiesmentioning

confidence: 99%

Cardiotoxicity From Human Epidermal Growth Factor Receptor‐2 (HER2) Targeted Therapies

Florido

Smith

Cuomo

et al. 2017

JAHA

View full text Add to dashboard Cite

“…In our study, hormone therapy was prescribed in 78% of cases with positive hormone receptors. Concerning trastuzumab, studies have shown a major benefit of its adjuvant use for one year in terms of relapse-free survival and overall survival (13) . It is also indicated in neo-adjuvant as well as in metastatic breast cancer.…”

Section: Discussionmentioning

confidence: 99%

Molecular Profile of Breast Cancer in Young Women in the Marrakech Region, Morocco: Experience of the Oncology Department CHU Mohamed VI Marrakech, Morocco

Bensallam¹,

Oumghar²,

Elomrani³

et al. 2017

IAM

View full text Add to dashboard Cite

Breast cancer in young women is increasing. The objective of this work was to analyze the epidemiological, clinical, therapeutic and prognostic characteristics of breast cancer in young women under 40 years. Through a retrospective study spread over five years from 1 January 2008 to 31 December 2012 and held at the Radiation Oncology Service of the University Hospital Mohammed VI Marrakech, we identified 272 cases of breast cancer in patients aged 40 years and under. The frequency of breast cancer in young women under 40 years was 24.42%. The average age was 35.6 years. The pauciparity and nulliparity were predominant (60.6%). 8 % had a family history of breast cancer. The self-examination of a nodule was predominant (93%). Tumors classified T2 were the most frequent (45%), followed by T4 tumors (29%).17% were metastatic immediately with predominant hepatic localizations (37.6%). It was Invasive breast carcinoma no special type (NST) in 82.3% of cases, with a predominance of SBR grades II and III (96%). Hormone receptors were positive in 68% of cases and HER2 overexpressed in 29 % of cases. 218 patients underwent surgery, which was radical in 68% and conservative in 21%. 149 had a locoregional irradiation. 71% received adjuvant chemotherapy with a predominance of FAC60 protocol (35%). Hormonotherapy was prescribed in 78% of cases with positive hormone receptors and trastuzumab in 73.8 % of patients over expressing HER2. After a median follow-up of 8.1 months, 41.4 % had relapses. Overall survival at three years was 70%, and the relapse free survival was 62%. Our study joins the data in the literature advocating more advanced forms and worse prognosis of breast cancer in young patients.

show abstract

“…In the PHARE trial, [6] 6 months of adjuvant trastuzumab was shown to be marginally less effective than the 12-month regimen in terms of DFS in a non-inferiority study. The 2-year DFS was 93.8% (95% CI 92.6 -94.9) in the 12-month group and 91.1% (95% CI 89.7 -92.4) in the 6-month group.…”

Section: Editorialmentioning

confidence: 99%

Short-course adjuvant trastuzumab will increase cure rates in patients with human epidermal growth factor receptor 2-positive breast cancer

Abratt¹

2017

S Afr Med J

View full text Add to dashboard Cite

6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial

Cited by 322 publications

References 11 publications

Cardiotoxicity From Human Epidermal Growth Factor Receptor‐2 (HER2) Targeted Therapies

Cardiotoxicity From Human Epidermal Growth Factor Receptor‐2 (HER2) Targeted Therapies

Molecular Profile of Breast Cancer in Young Women in the Marrakech Region, Morocco: Experience of the Oncology Department CHU Mohamed VI Marrakech, Morocco

Short-course adjuvant trastuzumab will increase cure rates in patients with human epidermal growth factor receptor 2-positive breast cancer

Contact Info

Product

Resources

About